International Journal of Research in Engineering, Science and Management
Volume 8, Issue 5, May 2025
https://www.ijresm.com | ISSN (Online): 2581-5792

Prevalence of Ascites in Hepatitis B and C: A Comparative Study

Ekedigwe J. Ekene[1*], J. Onubi[2], E. Elisha[3], A. Adeola[4], P. Eseigbe[5], A. A. G. Chima[6]
[1]*Associate Professor, Department of Radiology, Bingham University College of Medicine, Jos, Nigeria*
[2]*Senior Lecturer, Department of Chemical Pathology, Bingham University College of Medicine, Jos, Nigeria*
[3]*Senior Lecturer, Department of Medical Micro Biology and Parasitology, Bingham University College of Medicine, Jos, Nigeria*
[4]*Professor, Department of Medical Microbiology and Parasitology, Bingham University College of Medicine, Jos, Nigeria*
[5]*Associate Professor, Department of Family Medicine, Bingham University College of Medicine, Jos, Nigeria*
[6]*Professor, Bingham University College of Medicine, Jos, Nigeria*

***Abstract*: Ascites, the pathological accumulation of fluid in the peritoneal cavity, is a common and serious complication of chronic liver diseases, including those caused by Hepatitis B and C. This study evaluates the prevalence and associated risk factors of ascites in patients with Hepatitis B and C. Data were collected from 322 patients and analyzed to determine the relationship between ascites and these infections. The findings reveal significant differences in the prevalence of ascites between the two groups, highlighting the need for tailored management strategies.**

***Keywords*: Ascites, Hepatitis, Comparative study.**

1. Introduction

Ascites is a frequent manifestation of decompensated liver disease, resulting in significant morbidity and mortality. Hepatitis B and C are leading causes of chronic liver disease worldwide, and both can progress to cirrhosis and liver failure, conditions often complicated by ascites. Understanding the prevalence of ascites in these patients is crucial for early intervention and management. This study aims to provide a comparative analysis of ascites prevalence in patients with Hepatitis B and C and to identify associated clinical factors.

A. Problems to Solve

The primary problems addressed in this study include:

1. Determining the prevalence of ascites in patients with Hepatitis B and C.
2. Identifying the associated risk factors contributing to ascites development in these populations.
3. Comparing the clinical characteristics and outcomes of ascites in Hepatitis B versus Hepatitis C patients.

B. Aims and Objectives

The aims and objectives of this study are to:

1. Quantify and compare the prevalence of ascites in patients with Hepatitis B and C.
2. Investigate the clinical parameters associated with the presence and severity of ascites.
3. Provide data to inform clinical management and intervention strategies tailored to the specific needs of Hepatitis B and C patients.

2. Methods

A. Study Population

The study was conducted on a cohort of 322 patients diagnosed with Hepatitis B and C. Patients were recruited from a tertiary healthcare center, and their clinical data, including liver function tests, ultrasound findings, and the presence of ascites, were recorded.

B. Data Collection

Data were collected retrospectively from medical records. Key variables included demographic information, infection status, liver function tests, and ultrasound findings. Ascites was classified based on ultrasound findings into nil, mild, and moderate.

C. Statistical Analysis

Statistical analyses were performed using SPSS software. Chi-square tests were used to compare the prevalence of ascites between patients with Hepatitis B and C. Correlation analyses were conducted to determine the relationship between ascites and other clinical parameters.

Table 1
Demographic and clinical characteristics of patients

Variable	Total (n=322)	Hepatitis B (n=157)	Hepatitis C (n=165)
Male (%)	196 (60.9)	93 (59.2)	103 (62.4)
Male (n)	196	93	103
Female (%)	126 (39.1)	64 (40.8)	62 (37.6)
Female (n)	126	64	62
Mean Age (years)	45.2 ± 12.3	42.7 ± 11.8	47.1 ± 13.0

*Corresponding author: ekedigwekene@yahoo.co.uk

3. Results

A. Demographic and Clinical Characteristics

Table 1 presents the demographic distribution of the sample population. The majority of the patients were male, with a mean age of 45 years.

B. Prevalence of Ascites

The prevalence of ascites varied significantly between patients with Hepatitis B and those with Hepatitis C. Table 2 shows the distribution of ascites in patients with these infections.

Table 2
Prevalence of ascites in hepatitis B and C

Ascites Status	Hepatitis B (n=157)	Hepatitis C (n=165)	P-value
Nil (%)	92 (58.6)	106 (64.2)	0.001
Mild (%)	49 (31.2)	45 (27.3)	
Moderate (%)	16 (10.2)	14 (8.5)	

C. Correlation with Clinical Parameters

Table 3 presents the correlation between ascites and various clinical parameters, including liver size, gall bladder size, and spleen size.

Table 3
Correlation between ascites and clinical parameters

Parameter	Ascites Status	Mean Value ± SD	P-value
Liver Size (cm)	Nil	13.91 ± 1.60	0.427
	Mild	13.37 ± 1.84	
	Moderate	12.10 ± 0.0	
Gall Bladder Size 1 (cm)	Nil	5.68 ± 1.33	0.001
	Mild	5.03 ± 0.13	
	Moderate	-	
Gall Bladder Size 2 (cm)	Nil	2.10 ± 0.74	0.007
	Mild	2.65 ± 0.88	
	Moderate	-	
Spleen Size (cm)	Nil	8.34 ± 1.48	0.651
	Mild	9.03 ± 4.07	
	Moderate	8.00 ± 0.0	

4. Discussion

A. Ascites in Hepatitis B

The study found a significant prevalence of ascites in patients with Hepatitis B, with 41.4% of the patients exhibiting mild to moderate ascites. Chronic Hepatitis B can lead to cirrhosis, a major risk factor for ascites. The higher prevalence of ascites in Hepatitis B patients underscores the need for regular monitoring and early intervention to manage liver disease progression. Hepatitis B virus (HBV) infection causes liver inflammation and damage over time, leading to fibrosis and cirrhosis. Cirrhosis impairs liver function and leads to portal hypertension, a key factor in the development of ascites.

Management of ascites in Hepatitis B involves treating the underlying HBV infection with antiviral therapy to reduce viral replication and liver inflammation. In addition, diuretics and dietary sodium restriction are commonly used to manage fluid accumulation. Paracentesis may be required in severe cases to remove excess fluid from the peritoneal cavity. Regular follow-up and liver function monitoring are crucial in these patients to prevent complications and improve outcomes.

B. Ascites in Hepatitis C

Patients with Hepatitis C had a lower prevalence of ascites compared to those with Hepatitis B. However, Hepatitis C is known for its insidious progression to cirrhosis and liver failure, which can eventually lead to ascites. The findings suggest that while ascites may be less common initially in Hepatitis C, the risk increases with disease progression, highlighting the importance of early diagnosis and treatment. Hepatitis C virus (HCV) infection can lead to chronic hepatitis, fibrosis, and cirrhosis over several decades. Cirrhosis due to HCV increases the risk of portal hypertension and ascites formation.

The management of ascites in Hepatitis C involves antiviral therapy to achieve sustained virological response (SVR) and halt disease progression. Direct-acting antivirals (DAAs) have revolutionized HCV treatment, offering high cure rates and improved liver outcomes. Similar to Hepatitis B, diuretics and dietary sodium restriction are essential in managing fluid retention. Paracentesis may be necessary for refractory ascites, and patients should be monitored regularly for liver function and potential complications.

C. Comparative Analysis

The comparative analysis reveals that Hepatitis B patients are more likely to develop ascites than those with Hepatitis C. This may be attributed to differences in the pathophysiology and progression of liver damage between the two infections. HBV is known to cause more rapid liver fibrosis and cirrhosis compared to HCV. Additionally, the immune response to HBV and the resultant liver inflammation may be more severe, leading to quicker progression to cirrhosis and ascites.

The data also suggest that other factors, such as co-infections, alcohol consumption, and genetic predispositions, may play a role in the development of ascites. For instance, patients co-infected with HIV and HBV or HCV may have an accelerated course of liver disease and a higher risk of ascites. Similarly, excessive alcohol consumption exacerbates liver damage and increases the likelihood of ascites in both Hepatitis B and C patients.

5. Conclusion

Ascites is a prevalent complication in patients with chronic liver diseases due to Hepatitis B and C. The study highlights the importance of regular monitoring, early diagnosis, and tailored management strategies to prevent and manage ascites in these patients. Further research is needed to explore the underlying mechanisms and develop targeted therapies to reduce the burden of ascites in these populations. Improved understanding of the pathophysiology of ascites in Hepatitis B and C will aid in the development of more effective treatments and management protocols.

A. Addressing Issues in the Discussion

The discussion addresses several key issues:

1. *Ascites in Hepatitis B*: The study found a significant prevalence of ascites, emphasizing the need for regular

monitoring and early intervention.

2. *Ascites in Hepatitis C*: Though less prevalent initially, the risk of ascites increases with disease progression, underscoring the importance of early treatment.
3. *Comparative Analysis*: Differences in the pathophysiology between Hepatitis B and C, as well as other factors like co-infections and alcohol consumption, influence the prevalence of ascites.
4. *Management Strategies*: The discussion highlights the necessity of tailored management strategies for each type of hepatitis to effectively control and prevent ascites.

References

[1] European Association for the Study of the Liver. (2018). EASL Clinical Practice Guidelines: Management of decompensated cirrhosis. *Journal of Hepatology*, 69(2), 406-460.

[2] Schuppan, D., & Afdhal, N. H. (2008). Liver cirrhosis. *Lancet*, 371(9615), 838-851.

[3] World Health Organization. (2017). Global Hepatitis Report 2017. World Health Organization. Retrieved from https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/

[4] Friedman, S. L. (2003). Liver fibrosis — from bench to bedside. *Journal of Hepatology*, 38(Suppl 1), S38-S53.

[5] Lok, A. S. F., & McMahon, B. J. (2009). Chronic hepatitis B: update 2009. *Hepatology*, 50(3), 661-662.

[6] Lavanchy, D. (2011). Evolving epidemiology of hepatitis C virus. *Clinical Microbiology and Infection*, 17(2), 107-115.

[7] Naggie, S., & Sulkowski, M. S. (2012). Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. *Gastroenterology*, 142(6), 1324-1334.

[8] Garcia-Tsao, G., Friedman, S., Iredale, J., &Pinzani, M. (2010). Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. *Hepatology*, 51(4), 1445-1449.

[9] Gines, P., Quintero, E., Arroyo, V., Teres, J., Bruguera, M., Rimola, A., & Rodes, J. (1987). Compensated cirrhosis: natural history and prognostic factors. *Hepatology*, 7(1), 122-128.

[10] Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014). Liver cirrhosis. *Lancet*, 383(9930), 1749-1761.